Phase III development of Antisoma's ASA404 in lung cancer extended to Japan
Antisoma plc announced that ATTRACT-1, the Novartis phase III trial evaluating ASA404 as a first-line treatment for non-small cell lung cancer, is now enrolling patients in Japan. ATTRACT-1 has been enrolling patients in a variety of other countries since it began in April 2008. Extension of the trial to Japan follows the successful completion of a phase I study evaluating the safety of ASA404 in Japanese lung cancer patients.
Glyn Edwards, Antisoma's CEO, said "We're pleased that Japanese lung cancer patients can now participate in this key phase III trial of ASA404. This is an important step towards a potential application to market the drug in Japan."
ASA404 (DMXAA) is a small-molecule Tumour-Vascular Disrupting Agent (Tumour-VDA) which selectively disrupts tumour blood vessels, generating tumour death (necrosis) due to the resulting lack of blood flow in the tumour. The drug was discovered by Professors Bruce Baguley and William Denny and their teams at the Auckland Cancer Society Research Centre, University of Auckland, New Zealand. It was in-licensed by Antisoma from Cancer Research Ventures Limited (now Cancer Research Technology), the development and commercialisation company of the Cancer Research Campaign (now Cancer Research UK), in August 2001.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

New biomaterials from spider silk - Preventing infection, facilitating healing
RevaTen platelet-rich plasma shows promise as potential treatment for heart attacks
Generex Biotechnology to begin human trial of avian influenza vaccine
Evotec reaches milestone in integrated drug discovery and development partnership with Aeovian
Bio-molekula new distributor for Carlo Erba Reagents in Germany
Erasing a genetic mutation

Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy - Growth through investments in the “Big 3”

A new, highly sensitive chemical sensor uses protein nanowires - UMass Amherst team introduces high-performing 'green' electronic sensor

Beta cells from stem cells: Potential for cell replacement therapy - Quality control with CD177 can help save lots of time, efforts and money
Mutation of BAP1 gene passed down over centuries
GM chickens that don't transmit bird flu developed - Breakthrough could prevent future bird flu epidemics
